Literature DB >> 30218809

Bu Yang Huan Wu decoction prevents reperfusion injury following ischemic stroke in rats via inhibition of HIF-1 α, VEGF and promotion β-ENaC expression.

Zhen-Zhen Chen1, Xin Gong2, Qi Guo3, Hui Zhao4, Lei Wang5.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Bu Yang Huan Wu Decoction (BYHW) is a famous traditional Chinese medicine (TCM) formula used in China for the treatment of cerebral ischemic stroke. But the protective effects and underlining mechanisms of BYHW remain unclear. AIM OF THE STUDY: This study was designed to investigate the protective effects and underlining signaling mechanisms of BYHW on brain tissues in a rat model of cerebral ischemic reperfusion (I/R) injury.
MATERIALS AND METHODS: Liquid chromatography was used to verify the composition of BYHW. The cerebral edema and infarct volume were measured by magnetic resonance imaging (MRI). The morphology and ultrastructure of ischemic penumbra brain tissues were observed by hematoxylin-eosin (HE) and transmission electron microscopy (TEM). The expression levels of HIF-1 α, VEGF and β-ENaC were tested using immunohistochemistry technique, western blot and quantitative PCR analysis, respectively.
RESULTS: Administration of BYHW significantly decreased cerebral edema, rat neurological function scores, reduced brain infarct volume. At the same time, BYHW had protective effect on the blood-brain barrier (BBB), which improved the morphology and ultrastructure of ischemic penumbra brain tissues. BYHW treatment significantly decreased the protein and mRNA levels of HIF-1 α and VEGF compared with the model treatment. In addition, BYHW treatment significantly up-regulated the protein and mRNA levels of β-ENaC.
CONCLUSIONS: BYHW protected against cerebral I/R injury in MCAO rats through inhibiting the activation of the HIF-1 α /VEGF pathway and stabilizing ion channel of β-ENaC in brain, indicating that BYHW shows potential for stroke treatment in acute stage.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BBB; Cerebral edema; Cerebral ischemia reperfusion; HIF-1 α; VEGF; β-ENaC

Mesh:

Substances:

Year:  2018        PMID: 30218809     DOI: 10.1016/j.jep.2018.09.017

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  12 in total

1.  Preclinical Evidence of Paeoniflorin Effectiveness for the Management of Cerebral Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis.

Authors:  Anzhu Wang; Wei Zhao; Kaituo Yan; Pingping Huang; Hongwei Zhang; Xiaochang Ma
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

Review 2.  Therapeutic potential of traditional Chinese medicine for vascular endothelial growth factor.

Authors:  Yijia Mao; Lingkai Meng; Huayi Liu; Yuting Lu; Kuo Yang; Guangze Ouyang; Yanran Ban; Shuang Chen
Journal:  J Zhejiang Univ Sci B       Date:  2022-05-15       Impact factor: 5.552

3.  Buyang Huanwu Decoction Promotes Angiogenesis after Cerebral Ischemia by Inhibiting the Nox4/ROS Pathway.

Authors:  Jian Shen; Kaiyuan Huang; Yu Zhu; Kangli Xu; Renya Zhan; Jianwei Pan
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-31       Impact factor: 2.629

4.  Analysis of Clinical Efficacy of Traditional Chinese Medicine in Recovery Stage of Stroke: A Systematic Review and Meta-Analysis.

Authors:  Xue Zhang; Xiao-Fei Zhang; Lin Wang; Dong-Yan Guo; Jia-Min Zhang; Yong-Gang Chen; Zhi-Chao Wang; Li-Shan Pei; Jiang-Xue Chen; Ya-Jun Shi; Jun-Bo Zou
Journal:  Cardiovasc Ther       Date:  2020-09-19       Impact factor: 3.023

5.  Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke.

Authors:  Qiang Gao; Danfeng Tian; Zhenyun Han; Jingfeng Lin; Ze Chang; Dandan Zhang; Dayong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-26       Impact factor: 2.629

Review 6.  Effect of Panax notoginseng Saponins on Focal Cerebral Ischemia-Reperfusion in Rat Models: A Meta-Analysis.

Authors:  Tao Sun; Ping Wang; Ting Deng; Xingbao Tao; Bin Li; Ying Xu
Journal:  Front Pharmacol       Date:  2021-02-09       Impact factor: 5.810

7.  Yi-Zhi-Fang-Dai Formula Exerts Neuroprotective Effects Against Pyroptosis and Blood-Brain Barrier-Glymphatic Dysfunctions to Prevent Amyloid-Beta Acute Accumulation After Cerebral Ischemia and Reperfusion in Rats.

Authors:  Zhongkuan Lyu; Qiyue Li; Zhonghai Yu; Yuanjin Chan; Lei Fu; Yaming Li; Chunyan Zhang
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

Review 8.  HIF‑1α in cerebral ischemia (Review).

Authors:  Peiliang Dong; Qingna Li; Hua Han
Journal:  Mol Med Rep       Date:  2021-12-08       Impact factor: 2.952

Review 9.  Mitochondrial MPTP: A Novel Target of Ethnomedicine for Stroke Treatment by Apoptosis Inhibition.

Authors:  Yangxin Li; Jiayi Sun; Ruixia Wu; Jinrong Bai; Ya Hou; Yong Zeng; Yi Zhang; Xiaobo Wang; Zhang Wang; Xianli Meng
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

10.  The Combination of Astragalus membranaceus and Ligustrazine Protects Against Thrombolysis-Induced Hemorrhagic Transformation Through PKCδ/Marcks Pathway in Cerebral Ischemia Rats.

Authors:  Ruihuan Pan; Xialin Tang; Huajun Wang; Yan Huang; Kai Huang; Shanshan Ling; Mingchao Zhou; Jun Cai; Hongxia Chen; Yan Huang
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.